Package Leaflet: Information for the User
Zalasta 2.5 mg EFG tablets
Zalasta 5 mg EFG tablets
Zalasta 7.5 mg EFG tablets
Zalasta 10 mg EFG tablets
Zalasta 15 mg EFG tablets
Zalasta 20 mg EFG tablets
Olanzapine
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information:
Zalasta contains the active substance olanzapine. Zalasta belongs to a group of medicines called antipsychotics and is used to treat the following diseases:
Zalasta has been shown to prevent the recurrence of these symptoms in patients with bipolar disorder whose manic episodes have responded to treatment with olanzapine.
Do not take Zalasta
Warnings and precautions
Talk to your doctor or pharmacist before starting to take Zalasta
If you have any of the following diseases, tell your doctor as soon as possible:
If you suffer from dementia, you or your caregiver or family member should inform your doctor if you have ever had a stroke or a lack of blood flow to the brain.
As a routine precaution, if you are over 65 years old, it would be advisable for your doctor to check your blood pressure.
Children and adolescents
Patients under 18 years of age should not take Zalasta.
Using Zalasta with other medicines
Only use other medicines at the same time as Zalasta if your doctor authorizes it. You may feel drowsy if you combine Zalasta with antidepressants or medications for anxiety or that help you sleep (tranquilizers).
Tell your doctor or pharmacist if you are using, have recently used, or may need to use any other medicine.
Using Zalasta with alcohol
You should not drink alcohol if you have been given Zalasta, as it may cause drowsiness.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medicine. You should not take this medicine while breastfeeding, as small amounts of Zalasta may pass into breast milk.
The following symptoms may occur in newborns of mothers who have used Zalasta in the last trimester (last three months of pregnancy): tremors, muscle stiffness and/or weakness, drowsiness, agitation, breathing problems, and difficulty feeding. If your baby has any of these symptoms, contact your doctor.
Driving and using machines
There is a risk of drowsiness when taking Zalasta. If this happens, do not drive vehicles or use machinery. Consult your doctor.
Zalasta contains lactose
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine.
Follow exactly the administration instructions of this medicine given by your doctor. In case of doubt, consult your doctor or pharmacist again.
Your doctor will tell you how many Zalasta tablets to take and for how long. The daily dose of Zalasta ranges from 5 mg to 20 mg.
Consult your doctor if you experience symptoms again, but do not stop taking Zalasta unless your doctor tells you to.
Zalasta tablets should be taken once a day, following your doctor's instructions.
Try to take the tablets at the same time every day. You can take them with or without food.
The tablets should be swallowed whole with water.
If you take more Zalasta than you should
Patient who have taken more Zalasta than they should have experienced the following symptoms: rapid heartbeat, agitation/aggression, speech problems, unusual movements (especially of the face and tongue), and a reduced level of consciousness. Other symptoms may include: acute confusion, seizures (epilepsy), coma, a combination of fever, rapid breathing, sweating, muscle stiffness, and a state of confusion or drowsiness, slowing of respiratory rate, aspiration, increased or decreased blood pressure, and abnormal heart rhythms. Contact your doctor or go to the hospital immediately if you notice any of the above symptoms. Show the doctor the package with the tablets.
If you forget to take Zalasta
Take your tablets as soon as you remember. Do not take a double dose to make up for the forgotten dose.
If you stop taking Zalasta
Do not stop treatment just because you feel better. It is very important that you continue taking Zalasta while your doctor tells you to.
If you stop taking Zalasta suddenly, symptoms such as sweating, insomnia, tremors, anxiety, or nausea and vomiting may appear. Your doctor may suggest that you gradually reduce the dose before stopping treatment.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Contact your doctor immediately if you have:
Very common side effects (which can affect more than 1 in 10 people) include weight gain, drowsiness, and increased prolactin levels in the blood. In the early stages of treatment, some people may feel dizzy or faint (with slower heartbeats), especially when getting up from lying down or sitting. This feeling usually disappears on its own, but if it does not, consult your doctor.
Common side effects (which can affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating lipids, and temporary increases in liver enzymes at the start of treatment, increased blood sugar and urine levels, increased uric acid and creatine phosphokinase levels in the blood, increased appetite, dizziness, agitation, tremors, unusual movements (dyskinesia), constipation, dry mouth, skin rash, loss of strength, excessive fatigue, fluid retention that causes swelling of the hands, ankles, or feet, fever, joint pain, and sexual dysfunctions such as decreased libido in men and women or erectile dysfunction in men.
Uncommon side effects (which can affect up to 1 in 100 people) include hypersensitivity (e.g., inflammation of the mouth and throat, itching, skin rash), diabetes or worsening of diabetes, occasionally related to ketoacidosis (acetone in blood and urine) or coma, seizures, mostly related to a history of seizures (epilepsy), muscle stiffness or spasms (including eye movements), restless legs syndrome, speech problems, stuttering; slow pulse, sensitivity to sunlight, nosebleeds, abdominal distension, memory loss or forgetfulness, urinary incontinence, loss of urination ability, hair loss, absence or decrease of menstrual periods, and changes in the mammary gland in men and women, such as abnormal milk production or abnormal growth.
Rare side effects (which can affect up to 1 in 1000 people) include a drop in normal body temperature, abnormal heart rhythm, sudden unexplained death, pancreatitis, which causes severe stomach pain, fever, and discomfort, liver disease, with yellowing of the skin and the white parts of the eyes, muscle disorder that presents as unexplained pain and prolonged and/or painful erections.
Severe allergic reactions, such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have been reported. DRESS initially presents with symptoms similar to those of the flu, with a skin rash on the face that then spreads to other areas, fever, swelling of the lymph nodes, elevated liver enzyme levels in blood tests, and an increase in a type of white blood cell (eosinophilia).
During treatment with olanzapine, elderly patients with dementia may experience stroke, pneumonia, urinary incontinence, falls, extreme fatigue, visual hallucinations, a rise in body temperature, redness of the skin, and walking problems. Some deaths have been reported in this particular group of patients.
Zalasta may worsen symptoms in patients with Parkinson's disease.
Reporting of side effects
If you experience any side effects, talk to your doctor or nurse, even if they are not listed in this leaflet. You can also report them directly through the national reporting system included in Annex V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the carton. The expiration date is the last day of the month indicated.
Store in the original packaging to protect from light and moisture. This medicine does not require any special storage temperature.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
What Zalasta contains
See section 2 "Zalasta contains lactose".
Appearance of Zalasta and pack size
Zalasta 2.5 mg tablets are: round, slightly biconvex, light yellow with possibility of yellow spots.
Zalasta 5 mg tablets are: round, slightly biconvex, light yellow with possibility of yellow spots and engraved with "5" on one side.
Zalasta 7.5 mg tablets are: round, slightly biconvex, light yellow with possibility of yellow spots and engraved with "7.5" on one side.
Zalasta 10 mg tablets are: round, slightly biconvex, light yellow with possibility of yellow spots and engraved with "10" on one side.
Zalasta 15 mg tablets are: round, slightly biconvex, light yellow with possibility of yellow spots and engraved with "15" on one side.
Zalasta 20 mg tablets are: round, slightly biconvex, light yellow with possibility of yellow spots and engraved with "20" on one side.
Zalasta 2.5 mg tablets are available in boxes of 14, 28, 35, 56 and 70 tablets in blisters. Zalasta 5 mg tablets are available in boxes of 14, 28, 35, 56 and 70 tablets in blisters. Zalasta 7.5 mg tablets are available in boxes of 14, 28, 35, 56 and 70 tablets in blisters. Zalasta 10 mg tablets are available in boxes of 7, 14, 28, 35, 56 and 70 tablets in blisters.
Zalasta 15 mg tablets are available in boxes of 14, 28, 35, 56 and 70 tablets in blisters.
Zalasta 20 mg tablets are available in boxes of 14, 28, 35, 56 and 70 tablets in blisters.
Marketing authorisation holder
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Manufacturer
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
KRKA-POLSKA Sp. z o.o., ul. Równolegla 5, 02-235 Warszawa, Poland
TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany
You can request more information about this medicinal product by contacting the local representative of the marketing authorisation holder
Belgium KRKA Belgium, SA. Tel: + 32 (0) 487 50 73 62 | Lithuania UAB KRKA Lietuva Tel: + 370 5 236 27 40 |
Bulgaria KRKA Bulgaria EOOD Tel: + 359 (02) 962 34 50 | Luxembourg KRKA Belgium, SA. Tel: + 32 (0) 487 50 73 62 (BE) |
Czech Republic KRKA CR, s.r.o. Tel: + 420 (0) 221 115 150 | Hungary KRKA Magyarország Kereskedelmi Kft. Tel: + 36 (1) 355 8490 |
Denmark KRKA Sverige AB Tel: + 46 (0)8 643 67 66 (SE) | Malta
Tel: + 356 21 445 885 |
Germany TAD Pharma GmbH Tel: + 49 (0) 4721 606-0 | Netherlands KRKA Belgium, SA. Tel: + 32 (0) 487 50 73 62 (BE) |
Estonia KRKA, d.d., Novo mesto Eesti filiaal Tel: + 372 (0) 6 671 658 | Norway KRKA Sverige AB Tel: + 46 (0)8 643 67 66 (SE) |
Greece QUALIA PHARMA S.A. Tel: + 30 210 6256177 | Austria KRKA Pharma GmbH, Wien Tel: + 43 (0)1 66 24 300 |
Spain KRKA Farmacéutica, S.L. Tel: + 34 911 61 03 81 | Poland KRKA-POLSKA Sp. z o.o. Tel: + 48 (0)22 573 7500 |
France KRKA France Eurl Tel: + 33 (0)1 57 40 82 25 | Portugal KRKA Farmacêutica, Sociedade Unipessoal Lda. Tel: + 351 (0)21 46 43 650 |
Croatia KRKA - FARMA d.o.o. Tel: + 385 1 6312 100 | Romania KRKA Romania S.R.L., Bucharest Tel: + 4 021 310 66 05 |
Ireland KRKA Pharma Dublin, Ltd. Tel: + 353 1 293 91 80 | Slovenia KRKA, d.d., Novo mesto Tel: + 386 (0) 1 47 51 100 |
Iceland LYFIS ehf. Tel: + 354 534 3500 | Slovakia KRKA Slovensko, s.r.o. Tel: + 421 (0) 2 571 04 501 |
Italy KRKA Farmaceutici Milano S.r.l. Tel: + 39 02 3300 8841 | Finland KRKA Finland Oy Tel: + 358 20 754 5330 |
Cyprus Kipa Pharmacal Ltd. Tel: + 357 24 651 882 | Sweden KRKA Sverige AB Tel: + 46 (0)8 643 67 66 (SE) |
Latvia KRKA Latvija SIA Tel: + 371 6 733 86 10 | United Kingdom Consilient Health (UK) Ltd. Tel: + 44(0)203 751 1888 |
Date of last revision of this leaflet:
Detailed information on this medicinal product is available on the European Medicines Agency website http://www.ema.europa.eu/.